# Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin

> **NCT01309932** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 165 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **BIOLOGICAL:** Pegylated Interferon Lambda (pegIFNλ)
- **DRUG:** BMS-790052 (NS5A Inhibitor)
- **DRUG:** Ribavirin (RBV)
- **DRUG:** BMS-650032 (NS3 Protease Inhibitor)
- **BIOLOGICAL:** Pegylated Interferon Alfa-2a (pegIFNα-2a)
- **BIOLOGICAL:** Pegylated Interferon Lambda (pegIFNλ)
- **DRUG:** Ribavirin (RBV)
- **BIOLOGICAL:** Pegylated Interferon Lambda (pegIFNλ)
- **DRUG:** Ribavirin (RBV)
- **DRUG:** BMS-790052 (NS5A Inhibitor)
- **DRUG:** BMS-650032 (NS3 Protease Inhibitor)
- **DRUG:** Placebo (PBO) for BMS-650032 (Placebo for NS3 Protease Inhibitor)
- **DRUG:** Placebo (PBO) for BMS-790052 (Placebo for NS5A Inhibitor)
- **DRUG:** Placebo for Ribavirin (RBV)
- **DRUG:** Placebo for Ribavirin (RBV)

## Key facts

- **NCT ID:** NCT01309932
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2014-07
- **Final completion:** 2014-09
- **Target enrollment:** 165 (ACTUAL)
- **Last updated:** 2015-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01309932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01309932, "Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01309932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*